Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2024-04-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
独立董事专门会议工作制度（2024年度修订）
Governance Information Classification · 95% confidence The document is titled as a "独立董事专门会议工作制度" which translates to "Independent Directors Special Meeting Work System". It outlines the rules and procedures for independent directors' meetings within the company 康芝药业股份有限公司. The content focuses on governance structure, meeting protocols, voting rights, and responsibilities of independent directors. There is no financial data, no mention of financial results, no shareholder voting results, no announcements of report publications, or any other regulatory filings. The document is a governance-related internal policy or procedural document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-28 Chinese
监事会议事规则（2024年度修订）
Governance Information Classification · 95% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Meeting Rules' for 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It details the governance structure, duties, rights, meeting procedures, and responsibilities of the supervisory board members. The content focuses on internal governance rules and supervisory board operations rather than financial results, audit opinions, or management changes. There is no indication of financial data, audit reports, or announcements of voting results. The document is a governance-related internal rules report, fitting the category of Governance Information (CGR). The document length (6860 characters) and detailed content confirm it is the actual governance rules document, not an announcement or summary.
2024-04-28 Chinese
董事会提名委员会实施细则 （2024年度修订）
Governance Information Classification · 95% confidence The document is titled '董事会提名委员会实施细则' which translates to 'Board Nomination Committee Implementation Rules'. It details the structure, responsibilities, procedures, and rules of the board nomination committee of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). The content focuses on governance practices related to the nomination and appointment of directors and senior management, including committee composition, decision-making processes, and meeting protocols. There is no financial data, earnings information, or regulatory filing references. The document is a governance-related internal rules document rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR). The document length is 2599 characters, which is relatively short but contains substantive governance content, not just an announcement or notice.
2024-04-28 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled '康芝药业股份有限公司2024 年第一季度报告' which translates to 'Kangzhi Pharmaceutical Co., Ltd. 2024 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary on financial performance for the first quarter of 2024. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, specifically a quarter. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is an annual report, audit report, or other filing types. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-04-28 Chinese
关于终止部分募集资金投资项目并将剩余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 康芝药业股份有限公司 regarding the termination of certain fundraising investment projects and the permanent supplementation of remaining raised funds into working capital. It references specific fundraising projects, amounts raised, usage of funds, and approvals from the board and supervisory committees. The document includes detailed financial figures related to fundraising and investment projects, but it is not a full annual or interim financial report. It is also not a simple announcement of a report publication but a substantive disclosure about capital use and project termination. The content aligns with updates on company fundraising and capital structure changes, specifically about the use of raised funds. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (over 10,000 characters) and detailed financial data support this classification with high confidence.
2024-04-28 Chinese
海通证券关于康芝药业股份有限公司2023年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the 2023 annual verification of the storage and use of raised funds by Kangzhi Pharmaceutical Co., Ltd. It includes extensive financial data on fundraising, usage, balances, project investment progress, changes in investment projects, and audit opinions. The document references regulatory guidelines and includes an auditor's verification report. The content is focused on the annual use and management of raised funds, with detailed tables and explanations of project progress and fund allocation. This matches the characteristics of an Audit Report / Information (AR), which covers audit results and applied accounting principles related to specific financial aspects, here specifically the use of raised funds. The document is not a full Annual Report (10-K) or an Earnings Release (ER), nor is it a brief announcement or presentation. It is a standalone audit-related report on fundraising usage and compliance, fitting the AR category. FY 2023
2024-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.